Literature DB >> 3477319

Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.

J L Harousseau, P Hurteloup, J Reiffers, F Rigal-Huguet, M Hayat, P Dufour, P Y Le Prise, M Monconduit, J Jaubert, Y Carcassonne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3477319

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  6 in total

Review 1.  Acute myelogenous leukaemia in children.

Authors:  S O Lie
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

Review 2.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  A phase II study of oral idarubicin in advanced recurrent or refractory ovarian carcinoma.

Authors:  C J Williams
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

5.  Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.

Authors:  M Limonta; A Biondi; G Giudici; G Specchia; C Catapano; G Masera; T Barbui; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.